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Management of stable coronary artery disease patients: Very efficient
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Background: In studies and surveys involving stable coronary artery dis-
ease (CAD) patients, the global population often seems well managed; how-
ever, the question remains to know what is the proportion of patients who
benefit from every simple medical intervention improving the prognosis or
showing good quality of care.
Objective: To evaluate medical management of stable CAD outpatients in
France by calculating a progressive quality index.
Methods and Results: The INDYCE survey was conducted in a sample of
343 cardiologists in France in 2008. Each physician had to include consecu-
tively 10 stable CAD patients (absence of acute coronary syndrome or revas-
cularisation in the 6 months preceding enrolment).
3119 patients (male: 80 %, 68 ± 11 years old, diabetes: 24.3 %, hyperten-
sion: 61.6 %) were enrolled.
Medical therapy was in keeping with Guidelines (antiplatelet agents (AA) :
88.4 % ; statins : 85.9 % ; ACE-I/ARBs : 78.8 %, beta-blockers (BB) : 74.6
%). Patients suffered from mild to moderate symptoms (angina : 19.2 %,
NYHA class 0 or I : 43.5 %, NYHA class II : 46.9 %, NYHA class III : 9.3
% ; NYHA class IV : 0.3 %). Mean rest heart rate (HR) was of 64.2 ± 10.8
bpm, mean systolic and diastolic blood pressure (BP) of 131.8 ± 15.4 and 75.8
± 8.4 mmHg respectively.
However, when calculating a progressive quality index: 
(1) 44.69 % of the patients received an AA + a statin + an ACE-I/ARBs + a
BB
(2) 29.79 % had (1) and a systolic BP < 140 mmHg + a diastolic BP < 90
mmHg
(3) 23.02 % had (1) + (2) and a resting heart rate < 70 bpm
(4) 12.6 % had (1) + (2) + (3) and had a regular physical activity
(5) 6.96 % had (1) + (2) + (3) + (4) and had performed an exercise test during
the last 12 months
(6) 4.07 % had (1) + (2) + (3) + (4) + (5) and were asymptomatic (no angina
and NYHA class 0 or I)
Conclusion: Stable CAD patients do not raise attention because they are
often pauci-symptomatic. At a population level, they appear to be well man-
aged. However, building a quality index allows us to show that very few of
these patients benefit from every step of a simple medical management.
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The increased use of interventional cardiology (IC) procedures, while pro-
viding important benefits to patients, also contributes to their radiation expo-
sure. Radiation is a relatively weak carcinogen and demonstrating a radiation-
induced cancer risk remains difficult. Only very crude results of lifetime risk
assessment of cancer after IC procedures have been presented elsewhere, but
the age distribution of population, technical procedures actually applied and
target organs are also important to consider.
Based on a previous detailled description of clinical features and dosimetric
data (absorbed organ doses: lung and bone marrow) of an adult French popu-
lation undergoing IC procedure, and the latest radiation risk models (BEIR
VII), a specific risk assessment for lung cancer and leukaemia mortalities was
realized.
We considered patients having undergone either a coronary angiography or
cumulating coronary angiography and angioplasty, at age 40-75 years, and fol-
lowed until 85 years. Based on different scenarios of radiation exposure and
delivered-doses, the number of deaths from lung cancer or leukaemia due to
radiation per 1,000 general population spontaneous lung cancer or leukaemia
deaths respectively, was estimated. Preliminary results show that the risk of
specific radio-induced cancer in patients undergoing IC procedure exists even
if it remains relatively limited. Moreover, depending on patients’ age and type
of IC procedure, additional procedures appeared to increase the lifetime risk
estimates.
This study provides evidence of the potential radio-induced cancer risk in
IC. The limitations of such calculations are due to the difficulty to take into
account patients’ possible shorter life prognosis than in general population,
partly explained by comorbidities and coronary disease. Because of numerical
evolution of IC procedures, interventions to promote delivered-doses optimi-
zation and “ALARA” requirements may prevent or limit this risk.
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Despite the availability of specific guidelines, the management of dyslipi-
demia in practice is not optimal.
Objective and methodology: PRYSME, a non-interventional multicentre
study carried out with 1226 general practitioners, aimed to describe the imple-
mentation time of a lipid lowering treatment according to cardiovascular risk
level (primary objective) and to identify its determinants. Were eligible
patients treated for a dyslipidemia diagnosed less than 2 years ago. Demo-
graphic and clinical characteristics and circumstances of diagnosis and treat-
ment initiation were collected.
Results: 3268 patients were included (mean age: 57 years old, males:
64%). 26% were obese and 45% overweight.Only 12% had no cardiovascular
risk factors (CRF) at the time of dyslipidemia diagnosis. The most frequent
CRF were arterial hypertension (50%), smoking (43%), family history of pre-
mature coronary heart disease (28%), HDL-c <0.4g/l (20%) whereas 15% of
the patients had a personal history of cardiovascular disease. Dietary programs
were initially implemented for 98% of the patients. More than 90% were
treated with a statin. The implementation time of the treatment (evaluated
according to the biological confirmation of dyslipidemia), according to the ini-
tial number of CRF, was as following: 
The main determinant of an early implementation of a lipid lowering
therapy (≤ 3 months) was secondary prevention (OR=1.8). The number of
CRF had no significant impact.
 0 CRF 1 CRF 2 CRF ≥ 3 CRF Secondary prevention Total
[-3;0] months 34.3% 28.6% 27.1% 29.3% 49.1% 33.1%
]0;3] months 23.1% 26.2% 26.4% 24.0% 21.9% 23.9%
> 3 months 42.6% 45.3% 46.5% 46.8% 29.0% 43.0%
Chi-2 test : P<0.001
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Conclusion: This study underlines the lack of awareness towards cardio-
vascular risk factors in the management of dyslipidemia, particularly while
considering the implementation time of a lipid lowering therapy.
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Purpose: Current guidelines recommend lowering LDL-cholesterol below
2.6 mmol/L in patients with established cardiovascular disease. The potential ben-
efit of an additional decrease in LDL-cholesterol has been suggested for coronary
heart disease patients with diabetes or dysmetabolic profile, as they are at high risk
of recurrence. The aim of this analysis was to estimate the proportion of patients
with poor metabolic profile among those with established coronary heart disease.
Methods: A sample of French male patients with a history of acute coro-
nary syndrome was recruited from 2001 to 2004. Those with recent (in the
past two months) acute coronary syndrome were excluded.
Results: The sample comprised 824 men. Mean age was 60.3 years (stan-
dard deviation: 7.9), 22% of patients were still current smokers and 65% had
high blood pressure (≥ 140/90 or 130/80 mmHg if diabetes). Diabetes was
encountered in 32% of patients (20%, 36% and 38% from the 10-year age
group 45-54 to 65-74 years, respectively, p<0.0001), low HDL-cholesterol (<
1 mmol/L) was observed in 42% (48%, 43%, 36%, p=0.021), high triglycer-
ides (≥ 1.7 mmol/L) in 48% (58%, 49%, 38%, p<0.0001), and high non-HDL
cholesterol (≥ 3.4 mmol/L) in 74% of patients (84%, 77%, 64%, p<0.0001).
The combination of high non-HDL cholesterol and high triglycerides which
reflects the atherogenic potential associated with remnant lipoproteins was
encountered in 42% of patients (54%, 42%, 31%, p<0.0001) and 24% (32%,
24%, 17%, p<0.001) had a dysmetabolic profile (low HDL-cholesterol plus
high non HDL-cholesterol and elevated triglycerides). Overall, 48% of patients
(47%, 50%, 48%, p=0.706) presented either with diabetes or dysmetabolic
profile, and thus should be considered at very high risk.
Conclusions: These data suggest that almost one half of patients with estab-
lished coronary heart disease could be at very high risk, and may thus require a
more intensive strategy to control lipids and to reduce global cardiovascular risk.
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Background: The management of dyslipidemias remains a priority of pre-
ventive cardiology. The aim of this work was to assess lipids, lipoproteins and
dyslipidemias trends between 1996 and 2007 in France.
Methods: Two representative surveys of the general population were car-
ried out in Northern, in North-Eastern and in Southwestern areas of France in
1996-97 (n=3508) and in 2006-07 (n=3597). Men and women aged 35 to 64
years were included. The investigators recorded all the cardiovascular risk fac-
tors and a blood sample was drawn. Data have been rectified with the respec-
tive original populations to study a 10-year trend in the measured parameters.
Results: From 1996 to 2007, a significant 5.7% decrease in LDL-choles-
terol (C) levels was observed in adults aged 35-64 years (p<0.001). During
this same period a significant 7.8% increase in triglycerides was observed
(p<0.001). LDL-C variation was more striking in subjects treated with a lipid-
lowering drug, with a 17.6% reduction (p<0.001). Lipid-lowering drug preva-
lence increased significantly from 10.4% to 12.5% between the two periods
(p=0.004). In 1996-97, 33.7% of the dyslipidemic subjects were treated with
statins and 71.8% in 2006-07. In 2006-07, atorvastatin was the most com-
monly prescribed statin (35.8% of all statins) whereas the most common
fibrate was fenofibrate (87.2% of all fibrates). A decrease in most of dyslipi-
demias (LDL-C >4.1 mmol/L or triglycerides ≥2.3 mmol/L or HDL-C <1.05
mmol/L in men or <1.3 mmol/L in women) has also been observed at a 10-
year interval. On the other hand, we observed a significant increase in the
combination of hypertriglyceridemia with high LDL-C.
Conclusion: This study shows a favorable trend in LDL-C and dyslipi-
demias in France. The significant decrease in LDL-C observed among all the
subjects and more particularly among subjects treated with lipid-lowering drugs
should be incentive for physicians to support the management of all adults.
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Background: the implantation of pace maker or defibrillator expose to the
risk of infection of these devices. The use of antimicrobial prophylaxis before
implantation is not clearly recommended, because there are only few studies
that establish its benefit.
Patients and methods: we conducted a retrospective case control study
between 2004 and 2007, to determine the risk factor associated with infection,
especially if the administration of an antimicrobial prophylaxis is associated
with decrease of devices infection. Inclusion criteria were following: presence
of wound inflammation, or device externalisation, and Klug’s modified Dukes
criteria for endocarditis. All micro-organisms results from deep wound sample
or blood culture.
Results: 979 patients had a non valvular cardiac device during the study
period. 34 of them developed infectious complication (incidence 3.5 %) : 19
local infections, and 15 endocarditis. 70 patients constituted the age and sex
matched control population. Staphylococcus was isolated in 88 % of the cases.
27 % of them were S. aureus. 53 % of Staphylococcus were resistant to meti-
cillin. The risk factors associated with infection were following : number of
surgical interventions related to the cardiac devices (p < 0.001), early wound
inflammation or hematoma (p < 0.001), INR or partial thromboplastin time
ratio > 1.5 the day of implantation, fever before implantation (p< 0.001), more
infections after defibrillator implantation vs pace maker (p = 0.03) and
absence of antibioprohylaxis (p = 0.03). Antibioprophyxis were in majority of
case intra venous cephalosporin (16/17).
Conclusion: antibioprophylaxis and surveillance of anticoagulation could
be helpful to prevent infection after cardiac devices implantation; prospective
studies could be interesting to confirm these results. 
Table.  Risk factors for cardiac device infection
Risk factors for infection p
Number of surgical operation related to cardiac device p<0.001
Early wound inflammation or hematoma p<0.001
INR or partial thromboplastin time ratio > 1.5 p<0.015
Fever before implantation p<0.001
Defibrillator implantation versus pacemaker p=0.03
Absence of antibioprophylaxis p<0.03
